[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570540":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":35,"responsibleParty":56,"collaborators":12,"id":58,"slug":12,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":12,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":12,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":12,"overallStatus":38,"whyStopped":12,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"National Liver Institute, Egypt","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"biliary atresia without GCSF","NO_INTERVENTION","20 infants with the final diagnosis of biliary atresia type 3 (supported by the liver histology and intra-operative finding) for GCSF after Kasai operation will not receive GCSF.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"biliary atresia with GCSF","EXPERIMENTAL","20 infants with the final diagnosis of biliary atresia type 3 (supported by the liver histology and intra-operative finding) for GCSF after Kasai operation will receive GCSF.",[18],"Drug: Granulocyte Colony-Stimulating Factor",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Granulocyte Colony-Stimulating Factor","20 patients will receive subcutaneous GCSF at a daily dose of 10ug\u002Fkg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.",[14],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Marwa Narwa Foad Asker, master","CONTACT","+201008913103","marwafoadali@gmail.com",{"name":32,"role":28,"phone":33,"phoneExt":12,"email":34},"Behairy Behairy El Sayed Behairy, MD","+201001847754","behairyelsayed@yahoo.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"National Liver Institute","RECRUITING","Cairo","Menofia Governorate","32511","Egypt",{"type":44,"coordinates":45},"Point",[46,47],31.24967,30.06263,{"lat":47,"lon":46},[50,53],{"name":51,"role":28,"phone":33,"phoneExt":12,"email":52},"Behairy El Sayed El Sayed Behairy, MD","behairtelsayed@yahoo.com",{"name":54,"role":28,"phone":12,"phoneExt":12,"email":55},"Gasser Gasser El-Azab, MD","g_elazab@liver.menofia.edu.eg",{"type":57,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100570540",false,"NCT06708572","Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia","Inclusion Criteria:\n\n* Infants with initial diagnosis of biliary atresia with biliary atresia score \\> 23.927 will be allocated for Kasai porto-enterostomy with intra-operative cholangiogram reaching type 3 biliary atresia anatomy as a final diagnosis.\n\nExclusion Criteria:\n\n* Major cardiac, renal, pulmonary, neurological malformations or illnesses.\n* Hemoglobinopathies, such as sickle cell anemia\n* Active systemic infection.\n* White blood cell count \\> 20,000 cells\u002Fmm3.\n* Platelet count \\\u003C 40,000 cells\u002Fmm3 or ≥ 800,000 cells\u002Fmm3.\n* Purpura fulminans or unexplained vascular thrombotic conditions.",true,"ALL","20 Days","1 Year",{"count":68,"type":69},40,"ESTIMATED","INTERVENTIONAL",[72],"NA","The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.",[75,76],"Granulocyte Colony-stimulating Factor","Biliary Atresia","2024-12-09",{"date":79,"type":80},"2024-12-11","ACTUAL",{"date":82,"type":69},"2024-12",{"date":84,"type":69},"2026-10-30",{"name":5,"class":6},1]